X-twitter Linkedin Facebook-f Vimeo

Health

Companies engaged in biotechnology, pharmaceuticals, research services, home healthcare, hospital operations, long‑term care, and the manufacture and supply of medical equipment and supplies. The sector also includes pharmaceutical retailers and providers of health‑information services. UK‑listed companies in this sector include AstraZeneca plc, GlaxoSmithKline plc, Smith & Nephew plc, Hikma Pharmaceuticals plc, ConvaTec Group plc, Spire Healthcare plc and EMIS Group plc.

ETHY

Ethtry purchases additional 108 ETH under treasury strategy

Ethtry PLC has acquired a further 108.3253 ETH for approximately £162,488, increasing its total Ethereum holdings to 925 ETH as part of its ongoing treasury strategy...
VRCI

Verici Dx secures CPT PLA code for Protega and publishes PTRA study

Verici Dx has received a CPT PLA code for its Protega test and published analysis showing PTRA could deliver major U.S. healthcare savings in kidney transplant care...
Genflow Biosciences Plc

Healthspan takes centre stage in the longevity market

Longevity is moving beyond promises of longer life as consumers focus on healthspan, prevention and practical ways to age better...
Cizzle Biotechnology Holdings plc

Cizzle Bio builds US launch strategy for early cancer blood tests

Cizzle Bio is building a US commercial pathway for early cancer blood tests focused on lung and gastric cancer detection...
BIOG

Cogent Biosciences targets a defined rare disease opportunit

Cogent Biosciences is positioned in systemic mastocytosis, a rare disease market where diagnosis, testing and specialist awareness are central to the opportunity...
intravenous (IV) line

AstraZeneca’s Imfinzi plus BCG approved by FDA for high-risk bladder cancer

AstraZeneca’s Imfinzi has been approved in the US in combination with BCG for adults with BCG-naïve, high-risk non-muscle-invasive bladder cancer, based on Phase III POTOMAC trial results showing improved disease-free..
Nuformix plc

Nuformix strengthens financial position and advances NXP002 programme

Nuformix reported a reduced interim loss and a significantly improved cash position for the six months ended 31 March 2026, supported by successful fundraisings and progress with NXP002, including FDA..
Genflow Biosciences Plc

MASH creates a clearer investment case in liver disease

MASH is becoming a clearer healthcare investment theme as liver disease, metabolic risk and emerging treatment options converge...
Verici Dx Plc

Verici Dx takes aim at a persistent gap in kidney transplant care

Verici Dx is targeting a clear unmet need in kidney transplant care with molecular tests designed to improve rejection risk assessment and post-transplant monitoring...
CVS Group plc

CVS Group refinances £350m debt and launches £50m share buyback

CVS has refinanced its £350m bank facilities on improved terms, launched a £50m share buyback and acquired another small animal practice in Australia...
AstraZeneca

AstraZeneca’s Enhertu recommended for EU approval in HER2-positive solid tumours

AstraZeneca and Daiichi Sankyo’s Enhertu has received a positive CHMP opinion for adults with previously treated unresectable or metastatic HER2-positive solid tumours who have no satisfactory treatment options...
ETHY

Ethereum’s enterprise network case builds around scale and institutional use

Ethereum’s investor case is shifting from decentralised finance market share to enterprise-scale settlement, Layer-2 growth and institutional adoption...
Brava Health

Brava Health targets demand for smarter personalised healthcare

Brava Health is developing a smarter way for people to manage health data, receive personalised insights and navigate care with greater clarity...
CIZ

Cizzle Biotechnology sets date for Annual General Meeting

Cizzle Biotechnology has posted its AGM notice to shareholders. The meeting will be held on 16 June 2026 at Shakespeare Martineau LLP’s offices in London...
Cizzle Biotechnology Holdings plc

Cizzle Biotechnology targets early lung cancer detection market

Cizzle Biotechnology is targeting the early lung cancer detection market with a blood-based test aimed at addressing a major unmet medical need...
EDX

EDX Medical targets AIM growth with ultra-accurate cancer diagnostics

EDX Medical Chief Scientific Officer Professor Chris Evans discusses the company’s AIM admission, prostate cancer testing programme in Scotland, and plans to commercialise a range of advanced diagnostic tests...
Genflow Biosciences Plc

Pet healthspan focus opens a clearer senior care opportunity

Senior pet wellness is gaining relevance as owners focus on helping dogs and cats live better, not just longer...
VRCI

Verici Dx publishes clinical validation study for PTRA kidney transplant test

Verici Dx says a clinical validation study published in Kidney360 found its PTRA test outperformed conventional tools in predicting early acute rejection after kidney transplant...
GSK

Japan expands approval of GSK’s Arexvy to at-risk adults aged 18–49

GSK says Japan has expanded Arexvy eligibility to adults aged 18–49 at increased risk of RSV disease, including immunocompromised patients...
AstraZeneca

AstraZeneca and Daiichi Sankyo secure FDA approval for Enhertu in early breast cancer

The FDA has approved AstraZeneca and Daiichi Sankyo’s Enhertu for both neoadjuvant and adjuvant treatment of HER2-positive early breast cancer, based on results from the Phase III DESTINY-Breast11 and DESTINY-Breast05..

News and Interview Alerts

Subscribe Free

Company Presentations

Q&As

Hardman & Co

Green News

View all Sustainable sectors, Plcs and news >>  

Search

Search

Latest Interviews

BrokerTalk

Funds

View all Funds, Market Insights and news >> 

FTSE 100 News

UK Broker Ratings

Health

ETHY

Ethtry purchases additional 108 ETH under treasury strategy

Ethtry PLC has acquired a further 108.3253 ETH for approximately £162,488, increasing its total Ethereum holdings to 925 ETH as part of its ongoing treasury strategy...
VRCI

Verici Dx secures CPT PLA code for Protega and publishes PTRA study

Verici Dx has received a CPT PLA code for its Protega test and published analysis showing PTRA could deliver major U.S. healthcare savings in kidney transplant care...
Genflow Biosciences Plc

Healthspan takes centre stage in the longevity market

Longevity is moving beyond promises of longer life as consumers focus on healthspan, prevention and practical ways to age better...
Cizzle Biotechnology Holdings plc

Cizzle Bio builds US launch strategy for early cancer blood tests

Cizzle Bio is building a US commercial pathway for early cancer blood tests focused on lung and gastric cancer detection...
BIOG

Cogent Biosciences targets a defined rare disease opportunit

Cogent Biosciences is positioned in systemic mastocytosis, a rare disease market where diagnosis, testing and specialist awareness are central to the opportunity...
intravenous (IV) line

AstraZeneca’s Imfinzi plus BCG approved by FDA for high-risk bladder cancer

AstraZeneca’s Imfinzi has been approved in the US in combination with BCG for adults with BCG-naïve, high-risk non-muscle-invasive bladder cancer, based on Phase III POTOMAC trial results showing improved disease-free survival...
Nuformix plc

Nuformix strengthens financial position and advances NXP002 programme

Nuformix reported a reduced interim loss and a significantly improved cash position for the six months ended 31 March 2026, supported by successful fundraisings and progress with NXP002, including FDA Orphan Drug Designation in IPF...
Genflow Biosciences Plc

MASH creates a clearer investment case in liver disease

MASH is becoming a clearer healthcare investment theme as liver disease, metabolic risk and emerging treatment options converge...
Verici Dx Plc

Verici Dx takes aim at a persistent gap in kidney transplant care

Verici Dx is targeting a clear unmet need in kidney transplant care with molecular tests designed to improve rejection risk assessment and post-transplant monitoring...
CVS Group plc

CVS Group refinances £350m debt and launches £50m share buyback

CVS has refinanced its £350m bank facilities on improved terms, launched a £50m share buyback and acquired another small animal practice in Australia...
AstraZeneca

AstraZeneca’s Enhertu recommended for EU approval in HER2-positive solid tumours

AstraZeneca and Daiichi Sankyo’s Enhertu has received a positive CHMP opinion for adults with previously treated unresectable or metastatic HER2-positive solid tumours who have no satisfactory treatment options...
ETHY

Ethereum’s enterprise network case builds around scale and institutional use

Ethereum’s investor case is shifting from decentralised finance market share to enterprise-scale settlement, Layer-2 growth and institutional adoption...
Brava Health

Brava Health targets demand for smarter personalised healthcare

Brava Health is developing a smarter way for people to manage health data, receive personalised insights and navigate care with greater clarity...
CIZ

Cizzle Biotechnology sets date for Annual General Meeting

Cizzle Biotechnology has posted its AGM notice to shareholders. The meeting will be held on 16 June 2026 at Shakespeare Martineau LLP’s offices in London...
Cizzle Biotechnology Holdings plc

Cizzle Biotechnology targets early lung cancer detection market

Cizzle Biotechnology is targeting the early lung cancer detection market with a blood-based test aimed at addressing a major unmet medical need...
EDX

EDX Medical targets AIM growth with ultra-accurate cancer diagnostics

EDX Medical Chief Scientific Officer Professor Chris Evans discusses the company’s AIM admission, prostate cancer testing programme in Scotland, and plans to commercialise a range of advanced diagnostic tests...
Genflow Biosciences Plc

Pet healthspan focus opens a clearer senior care opportunity

Senior pet wellness is gaining relevance as owners focus on helping dogs and cats live better, not just longer...
VRCI

Verici Dx publishes clinical validation study for PTRA kidney transplant test

Verici Dx says a clinical validation study published in Kidney360 found its PTRA test outperformed conventional tools in predicting early acute rejection after kidney transplant...
GSK

Japan expands approval of GSK’s Arexvy to at-risk adults aged 18–49

GSK says Japan has expanded Arexvy eligibility to adults aged 18–49 at increased risk of RSV disease, including immunocompromised patients...
AstraZeneca

AstraZeneca and Daiichi Sankyo secure FDA approval for Enhertu in early breast cancer

The FDA has approved AstraZeneca and Daiichi Sankyo’s Enhertu for both neoadjuvant and adjuvant treatment of HER2-positive early breast cancer, based on results from the Phase III DESTINY-Breast11 and DESTINY-Breast05 trials...
Load More

News and Interview Alerts

Subscribe Free

Company Presentations

Q&As

Hardman & Co

Green News

View all Sustainable sectors, Plcs and news >>  

Search

Search

Latest interviews

Broker Talk

Funds

View all Funds, Market Insights and news >> 

FTSE 100 News

UK Broker Ratings

Health

Latest Interviews

FTSE 100 News

FTSE 250 News

News and Interview Alerts

Subscribe Free

Company Presentations

Q&As

Hardman & Co

BrokerTalk

FTSE 100

Funds

View all Funds, Market Insights and news >> 

Green News

View all Sustainable sectors, Plcs and news >>  

UK Broker Ratings

Follow us on Social Media:

Home X-twitter Linkedin Facebook Spotify Apple